Sol-Gel Technologies Ltd. (SLGL) Form 6-K — May 28, 2026
Sol-Gel Technologies (SLGL) reported Q1 2026 results with a net loss of $3.7 million, a significant improvement from the $8.8 million loss in the prior year, driven by reduced R&D spend. The company raised $33.1 million in an oversubscribed underwritten offering in March 2026, extending its cash runway into the first quarter of 2028. The company received a Notice of Allowance for a method-of-use patent for its lead candidate SGT-610 (patidegib), extending intellectual property protection until 2044. This patent covers a critical aspect of topical patidegib therapy for Gorlin syndrome, a rare genetic disorder.
Key figures
- Revenue
- 108000
- Revenue Yoy
- -89%
- Cash Position
- 52800000
- Gross Proceeds
- 33100000
- Shares Outstanding
- 3268991
- Ga expenses
- 1177000
- Rd expenses
- 2786000
- Operating loss
- 3855000
- Cash runway end
- Q1 2028
- Patent expiry year
- 2044
- Potential annual royalties 2031
- 10000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.